- Home
- MDXH vs PRQR Comparison
MDXH vs PRQR Comparison
Compare MDXH & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- PRQR
- Stock Information
- Founded
- MDXH 2003
- PRQR 2012
- Country
- MDXH Belgium
- PRQR Netherlands
- Employees
- MDXH N/A
- PRQR N/A
- Industry
- MDXH
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- PRQR Health Care
- Exchange
- MDXH Nasdaq
- PRQR Nasdaq
- Market Cap
- MDXH 203.4M
- PRQR 224.4M
- IPO Year
- MDXH 2021
- PRQR 2014
- Fundamental
- Price
- MDXH $4.92
- PRQR $2.75
- Analyst Decision
- MDXH Buy
- PRQR Strong Buy
- Analyst Count
- MDXH 1
- PRQR 7
- Target Price
- MDXH $6.00
- PRQR $8.14
- AVG Volume (30 Days)
- MDXH 274.6K
- PRQR 649.8K
- Earning Date
- MDXH 11-12-2025
- PRQR 11-07-2025
- Dividend Yield
- MDXH N/A
- PRQR N/A
- EPS Growth
- MDXH N/A
- PRQR N/A
- EPS
- MDXH N/A
- PRQR N/A
- Revenue
- MDXH $98,953,000.00
- PRQR $20,129,184.00
- Revenue This Year
- MDXH $24.43
- PRQR N/A
- Revenue Next Year
- MDXH $21.00
- PRQR N/A
- P/E Ratio
- MDXH N/A
- PRQR N/A
- Revenue Growth
- MDXH 22.56
- PRQR 8.65
- 52 Week Low
- MDXH $1.35
- PRQR $1.07
- 52 Week High
- MDXH $5.33
- PRQR $4.21
- Technical
- Relative Strength Index (RSI)
- MDXH 64.64
- PRQR 55.89
- Support Level
- MDXH $4.71
- PRQR $2.61
- Resistance Level
- MDXH $5.33
- PRQR $3.00
- Average True Range (ATR)
- MDXH 0.30
- PRQR 0.25
- MACD
- MDXH 0.05
- PRQR -0.02
- Stochastic Oscillator
- MDXH 72.11
- PRQR 61.11
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.